Significance of myocardial tenascin-C expression in left ventricular remodelling and long-term outcome in patients with dilated cardiomyopathy

European Journal of Heart Failure

Volumn 18, Issue 4, 2016, Pages 375-385

  Yokokawa, Tetsuro ^a   Sugano, Yasuo ^a   Nakayama, Takafumi ^a   Nagai, Toshiyuki ^a   Matsuyama, Taka Aki ^a   Ohta Ogo, Keiko ^a   Ikeda, Yoshihiko ^a   Ishibashi Ueda, Hatsue ^a   Nakatani, Takeshi ^a   Yasuda, Satoshi ^a   Takeishi, Yasuchika ^b   Ogawa, Hisao ^a   Anzai, Toshihisa ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Dilated cardiomyopathy; Heart failure; Left ventricular remodelling; Prognosis; Tenascin C

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; SULFONYLUREA; TENASCIN; COLLAGEN;

ADULT; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE; HEART MUSCLE BIOPSY; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL; AGED; CARDIAC MUSCLE; CARDIOMYOPATHY, DILATED; COMORBIDITY; DIAGNOSTIC IMAGING; HEART STROKE VOLUME; KAPLAN MEIER METHOD; METABOLISM; MULTIVARIATE ANALYSIS; SURVIVAL ANALYSIS; TIME FACTOR;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOMYOPATHY, DILATED; COLLAGEN; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; SURVIVAL ANALYSIS; TENASCIN; TIME FACTORS; VENTRICULAR REMODELING;

EID: 84954270877     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.464     Document Type: Article

References (28)

1. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M,. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424-1433.
2. Jefferies JL, Towbin JA,. Dilated cardiomyopathy. Lancet 2010; 375: 752-762.
3. Imanaka-Yoshida K., Tenascin-C in cardiovascular tissue remodeling: from development to inflammation and repair. Circ J 2012; 76: 2513-2520.
4. Okamoto H, Imanaka-Yoshida K,. Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc Ther 2012; 30: e198-e209.
5. Imanaka-Yoshida K, Aoki H,. Tenascin-C and mechanotransduction in the development and diseases of cardiovascular system. Front Physiol 2014;5:283.
6. Nishioka T, Onishi K, Shimojo N, Nagano Y, Matsusaka H, Ikeuchi M, Ide T, Tsutsui H, Hiroe M, Yoshida T, Imanaka-Yoshida K,. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2010; 298: H1072-H1078.
7. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R,. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007; 50: 1914-1931.
8. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN,. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404-1413.
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ,. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
10. Teichholz LE, Kreulen T, Herman MV, Gorlin R,. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37: 7-11.
11. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F,. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 1993; 22: 808-815.
12. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M,. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006; 47: 2319-2325.
13. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE,. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011; 4: 98-108.
14. Cohn JN, Ferrari R, Sharpe N,. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-582.
15. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992; 86: 431-438.
16. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR,. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36: 2072-2080.
17. Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Knoll R, Leite-Moreira AF, Lourenco AP, Mayr M, Thum T, Tocchetti CG,. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail 2014; 16: 494-508.
18. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG,. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97: 1708-1715.
19. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A,. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007; 71: 327-330.
20. Fujimoto N, Onishi K, Sato A, Terasaki F, Tsukada B, Nozato T, Yamada T, Imanaka-Yoshida K, Yoshida T, Ito M, Hiroe M,. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Card Fail 2009; 15: 898-905.
21. Imanaka-Yoshida K, Matsumoto K, Hara M, Sakakura T, Yoshida T,. The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation 2003; 71: 291-298.
22. Franz M, Berndt A, Neri D, Galler K, Grun K, Porrmann C, Reinbothe F, Mall G, Schlattmann P, Renner A, Figulla HR, Jung C, Kuthe F,. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B(+) tenascin-C and ED-A(+) fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis. Int J Cardiol 2013; 168: 5344-5351.
23. Midwood KS, Hussenet T, Langlois B, Orend G,. Advances in tenascin-C biology. Cell Mol Life Sci 2011; 68: 3175-3199.
24. Franz M, Berndt A, Grun K, Kuethe F, Fritzenwanger M, Figulla HR, Jung C,. Serum levels of tenascin-C variants in congestive heart failure patients: comparative analysis of ischemic, dilated, and hypertensive cardiomyopathy. Clin Lab 2014; 60: 1007-1013.
25. Mariappan MM, DeSilva K, Sorice GP, Muscogiuri G, Jimenez F, Ahuja S, Barnes JL, Choudhury GG, Musi N, DeFronzo R, Kasinath BS,. Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney. Am J Physiol Cell Physiol 2014; 306: C202-C211.
26. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, Bijlsma JW, Lafeber FP, Baynes JW, TeKoppele JM,. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000; 275: 39027-39031.
27. Gulati A, Ismail TF, Jabbour A, Alpendurada F, Guha K, Ismail NA, Raza S, Khwaja J, Brown TD, Morarji K, Liodakis E, Roughton M, Wage R, Pakrashi TC, Sharma R, Carpenter JP, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK,. The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. Circulation 2013; 128: 1623-1633.
28. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ,. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 2008; 117: 1436-1448.